



10100SJ0043 Engrossed

LRB101 11737 MST 58399 r

1 SENATE JOINT RESOLUTION NO. 43

2 (As Amended by Senate Amendment No. 1)

3 WHEREAS, The human papillomavirus (HPV) is the most common  
4 sexually transmitted virus in the United States; nearly 14  
5 million people become infected each year; and

6 WHEREAS, HPV causes approximately 33,700 cases of  
7 HPV-associated cancers each year, including cervical, anal,  
8 and oropharyngeal cancers; and

9 WHEREAS, 9-valent HPV vaccine protects against nine types  
10 of HPV infection; and

11 WHEREAS, The HPV vaccine was tested before being licensed  
12 by the Food and Drug Administration and continues to be  
13 monitored by the Centers for Disease Control and Prevention and  
14 the Food and Drug Administration; and

15 WHEREAS, The most common side effects are mild and include  
16 pain, redness, or swelling in the arm where the shot is given;  
17 dizziness, fainting, nausea, and headaches can also occur; and

18 WHEREAS, The American Academy of Pediatrics (AAP) and the  
19 Advisory Committee on Immunization Practices (ACIP) recommend  
20 two doses of HPV vaccine for males and females ages 11-12; the

1 vaccine is approved for men and women through age 45; and

2 WHEREAS, In Illinois, only 50 percent of males and females  
3 ages 13-17 years were up to date on HPV vaccination in 2017;  
4 therefore, be it

5 RESOLVED, BY THE SENATE OF THE ONE HUNDRED FIRST GENERAL  
6 ASSEMBLY OF THE STATE OF ILLINOIS, THE HOUSE OF REPRESENTATIVES  
7 CONCURRING HEREIN, that we encourage adolescents in Illinois to  
8 receive the HPV vaccine to protect themselves against HPV  
9 infection and HPV-related cancers.